HCV: The Journey from Discovery to a Cure: Volume I: Topics in Medicinal Chemistry, cartea 31
Editat de Michael J. Sofiaen Limba Engleză Paperback – 16 dec 2020
Hepatitis C is a liver disease caused by the hepatitis C virus (HCV) and infects approximately 75 million individuals worldwide. It is also one of the major causes of liver cancer and liver transplants. The elucidation of the HCV genome, and the development of a whole cell system to study the virus spurred the search for novel direct acting antiviral drugs to cure this disease. This global effort culminated in the development of direct acting antiviral drugs that led to cure rates approaching 100% in all patient populations after only 8-12 weeks of therapy. These efforts resulted in one of the greatest achievements in public health and provides the potential for eliminating HCV as a major disease worldwide.
This volume is aimed at a broad audience of academic and industrial scientists interested in the discovery and development of drugs to treat viral diseases and those interested in reading about one of the most unique accomplishments in biomedical research. The volume will provide a one of a kind reference work that highlights the many efforts, from the discovery of the HCV virus, to the invention of breakthrough medicines and their use in the real world to cure patients. It is the companion book to the volume "HCV: The Journey from Discovery to a Cure - Volume II".
| Toate formatele și edițiile | Preț | Express |
|---|---|---|
| Paperback (2) | 2383.33 lei 43-57 zile | |
| Springer International Publishing – 16 dec 2020 | 2383.33 lei 43-57 zile | |
| Springer International Publishing – 26 aug 2021 | 2385.18 lei 43-57 zile | |
| Hardback (2) | 2389.42 lei 43-57 zile | |
| Springer International Publishing – 3 dec 2019 | 2389.42 lei 43-57 zile | |
| Springer International Publishing – 8 feb 2020 | 2391.09 lei 43-57 zile |
Din seria Topics in Medicinal Chemistry
- 24%
Preț: 742.85 lei - 18%
Preț: 1187.50 lei - 18%
Preț: 908.71 lei - 18%
Preț: 909.20 lei - 18%
Preț: 1174.28 lei - 15%
Preț: 623.90 lei - 18%
Preț: 1174.57 lei - 18%
Preț: 1173.67 lei - 18%
Preț: 1172.91 lei - 18%
Preț: 1170.51 lei - 18%
Preț: 1170.20 lei - 18%
Preț: 1750.49 lei - 18%
Preț: 1172.17 lei - 18%
Preț: 1169.43 lei - 18%
Preț: 1171.86 lei - 18%
Preț: 1327.65 lei - 18%
Preț: 1172.77 lei - 18%
Preț: 1172.61 lei - 18%
Preț: 1330.67 lei - 18%
Preț: 2013.31 lei - 18%
Preț: 1604.58 lei - 18%
Preț: 1751.10 lei - 18%
Preț: 1171.86 lei - 18%
Preț: 1176.86 lei - 18%
Preț: 1183.55 lei - 18%
Preț: 2372.85 lei - 18%
Preț: 1746.24 lei - 18%
Preț: 1752.16 lei
Preț: 2383.33 lei
Preț vechi: 2906.51 lei
-18% Nou
Puncte Express: 3575
Preț estimativ în valută:
456.11€ • 482.36$ • 380.46£
456.11€ • 482.36$ • 380.46£
Carte tipărită la comandă
Livrare economică 30 decembrie 24 - 13 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9783030282097
ISBN-10: 3030282090
Pagini: 463
Ilustrații: VIII, 463 p. 1 illus.
Dimensiuni: 155 x 235 mm
Greutate: 0.65 kg
Ediția:1st ed. 2019
Editura: Springer International Publishing
Colecția Springer
Seria Topics in Medicinal Chemistry
Locul publicării:Cham, Switzerland
ISBN-10: 3030282090
Pagini: 463
Ilustrații: VIII, 463 p. 1 illus.
Dimensiuni: 155 x 235 mm
Greutate: 0.65 kg
Ediția:1st ed. 2019
Editura: Springer International Publishing
Colecția Springer
Seria Topics in Medicinal Chemistry
Locul publicării:Cham, Switzerland
Cuprins
Identification of the virus, the medical need and clearing the blood supply.- Mapping the HCV genome.- The molecular virology of HCV.- The development of the HCV replicon system.- The Evolution of IFN therapy for HCV.- Evolution of HCV NS5B Non-Nucleoside Inhibitors.- Evolution of HCV NS5B Nucleoside & Nucleotide Inhibitors.- Discovery and Development of Sofosbuvir.- Discovery of Beclabuvir.- Discovery of Dasabuvir.- Evolution of HCV NS3/4 protease inhibitors.- Discovery and Development of Telaprevir.- Discovery and Development of Boceprevir.- Discovery and Development of Asunaprevir.-Discovery and Development of Grazoprevir.- Discovery and Development of Simeprevir.- Discovery and Development of Paritaprevir & Glecaprevir.
Notă biografică
Michael J. Sofia, Ph.D. is currently Chief Scientific Officer and co-founder at Arbutus Biopharma, Inc., a company focused on the discovery and development of therapies to treat hepatitis B. He also holds a professorship at the Baruch S. Blumberg Institute and an Adjunct Professorship at the Drexel University School of Medicine.
Previously, Mike Sofia was Senior Vice President of Chemistry and Senior Advisor at Gilead Sciences and was Sr. Vice President of Chemistry at Pharmasset, Inc until Pharmasset’s acquisition by Gilead in Jan 2012.
Mike Sofia previously held research and research management positions at Bristol-Myers Squibb, Intercardia Research Labs (formerly Transcell Technologies) and Eli Lilly & Co. He did his postdoctoral training in synthetic organic chemistry as an NIH fellow at Columbia University and received his Ph.D. in organic chemistry from the University of Illinois, Urbana-Champaign. He earned his B.A. degree in chemistry from Cornell University.
Mike has introduced numerous drugs into clinical development for the treatment of infectious diseases and inflammatory diseases. He is the principle inventor of sofosbuvir (Sovaldiâ and Harvoniâ) currently marketed as a treatment for the cure of HCV infection. Mike is the recipient of numerous awards including the 2015 ACS Heroes of Chemistry Award, the Economist Magazine’s 2015 Innovation Award in Biosciences, the 2016 IUPAC-Richter Prize, the 2016 Lasker-Debakey Award in Clinical Medical Research and the 2017 Gertrude Elion Award from the International Society for Antiviral Research.
Previously, Mike Sofia was Senior Vice President of Chemistry and Senior Advisor at Gilead Sciences and was Sr. Vice President of Chemistry at Pharmasset, Inc until Pharmasset’s acquisition by Gilead in Jan 2012.
Mike Sofia previously held research and research management positions at Bristol-Myers Squibb, Intercardia Research Labs (formerly Transcell Technologies) and Eli Lilly & Co. He did his postdoctoral training in synthetic organic chemistry as an NIH fellow at Columbia University and received his Ph.D. in organic chemistry from the University of Illinois, Urbana-Champaign. He earned his B.A. degree in chemistry from Cornell University.
Mike has introduced numerous drugs into clinical development for the treatment of infectious diseases and inflammatory diseases. He is the principle inventor of sofosbuvir (Sovaldiâ and Harvoniâ) currently marketed as a treatment for the cure of HCV infection. Mike is the recipient of numerous awards including the 2015 ACS Heroes of Chemistry Award, the Economist Magazine’s 2015 Innovation Award in Biosciences, the 2016 IUPAC-Richter Prize, the 2016 Lasker-Debakey Award in Clinical Medical Research and the 2017 Gertrude Elion Award from the International Society for Antiviral Research.
Textul de pe ultima copertă
Hepatitis C is a liver disease caused by the hepatitis C virus (HCV) and infects approximately 75 million individuals worldwide. It is also one of the major causes of liver cancer and liver transplants. The elucidation of the HCV genome, and the development of a whole cell system to study the virus spurred the search for novel direct acting antiviral drugs to cure this disease. This global effort culminated in the development of direct acting antiviral drugs that led to cure rates approaching 100% in all patient populations after only 8-12 weeks of therapy. These efforts resulted in one of the greatest achievements in public health and provides the potential for eliminating HCV as a major disease worldwide.
This volume is aimed at a broad audience of academic and industrial scientists interested in the discovery and development of drugs to treat viral diseases and those interested in reading about one of the most unique accomplishments in biomedical research. The volume will provide a one of a kind reference work that highlights the many efforts, from the discovery of the HCV virus, to the invention of breakthrough medicines and their use in the real world to cure patients. It is the companion book to the volume "HCV: The Journey from Discovery to a Cure - Volume II".
Caracteristici
Provides a comprehensive compilation of discoveries that led to the cure for HCV by the leading researchers in the field Traces all aspects of HCV research that contributed to the development of key drugs and to the identification of important drug Provides an authoritative history of the journey to find a cure for HCV with accounts from the key researchers themselves